ODC Import Licence secured - ODC Export Licence secured Queensland Bauxite Limited (ASX:QBL) is delighted to announce that Medcan Australia (“Medcan”), has now been issued with both an Import & Export Licence under the ODC (Office of Drug Control).
These licences now allow Medcan, subject to individual permit issue, the ability to capitalise on the significant international and local opportunities by both importing and exporting a wide range of Cannabis products including, but not limited to: -Cultivars -Dried flower finished products -Full extract oil and tinctures finished products -Medicinal cannabis products manufactured in Australia under a GMP Licence -Medicinal cannabis products listed as export-only or registered in the ARTG -Extracts of cannabis (or cannabis resin) manufactured under a Narcotic Drugs Act 1967 Licence that are not in the final dosage form -The Canntab XR Pills produced in Canada As previously announced, QBL has entered into an agreement to acquire 100% of Medcan.
Medcan Australia’s CEO, Craig Cochran commented “We are extremely happy to add the import and export licences to our current suite of licences. This brings Medcan Australia another step closer to our vision of providing patient specific Medicinal Cannabis products to the people that need them most. It also allows us the ability to capitalise on various opportunities in the international market immediately.”
Pnina Feldman, Executive Chairperson of QBL stated “We are very pleased to see the continued development of Medcan during this interim period. We continue to be impressed with the knowledge and professionalism of the Medcan team to have been one of the very few in Australia to have achieved the granting of all these valuable licences. We are confident that Medcan, together with our international network and dedicated and experienced team, will immediately be able to build on these achievements in the short term to create much shareholder wealth.”
Further information on the most significant announcement to date, can be found on our website. Explanation on the two acquisitions, for both MCL (Medical Cannabis Ltd) and Medcan – Medical Cannabis. We know have full intrest in these two businesses and moving forward. Post 207 and 215 is also informative about the new QBL.
https://www.queenslandbauxite.com/ Now QBL states; ”QBL Cannabis Group” – the recreational side of cannabis is also on the wall (in the long run I guess), MCL director Andrew speaks about it in a recent interview on TV.
These licences now allow Medcan, subject to individual permit issue, the ability to capitalise on the significant international and local opportunities by both importing and exporting a wide range of Cannabis products including, but not limited to: -Cultivars -Dried flower finished products -Full extract oil and tinctures finished products -Medicinal cannabis products manufactured in Australia under a GMP Licence -Medicinal cannabis products listed as export-only or registered in the ARTG -Extracts of cannabis (or cannabis resin) manufactured under a Narcotic Drugs Act 1967 Licence that are not in the final dosage form -The Canntab XR Pills produced in Canada As previously announced, QBL has entered into an agreement to acquire 100% of Medcan.
Medcan Australia’s CEO, Craig Cochran commented “We are extremely happy to add the import and export licences to our current suite of licences. This brings Medcan Australia another step closer to our vision of providing patient specific Medicinal Cannabis products to the people that need them most. It also allows us the ability to capitalise on various opportunities in the international market immediately.”
Pnina Feldman, Executive Chairperson of QBL stated “We are very pleased to see the continued development of Medcan during this interim period. We continue to be impressed with the knowledge and professionalism of the Medcan team to have been one of the very few in Australia to have achieved the granting of all these valuable licences. We are confident that Medcan, together with our international network and dedicated and experienced team, will immediately be able to build on these achievements in the short term to create much shareholder wealth.”
Further information on the most significant announcement to date, can be found on our website. Explanation on the two acquisitions, for both MCL (Medical Cannabis Ltd) and Medcan – Medical Cannabis. We know have full intrest in these two businesses and moving forward. Post 207 and 215 is also informative about the new QBL.
https://www.queenslandbauxite.com/ Now QBL states; ”QBL Cannabis Group” – the recreational side of cannabis is also on the wall (in the long run I guess), MCL director Andrew speaks about it in a recent interview on TV.
1
1
Robert
